The pivot to FDA-approved generics as patents expire in various countries follows a year of soaring demand for the branded ...

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

GoodRx reports that HSA and FSA can cover weight-loss expenses if prescribed for medical conditions, requiring a letter of ...

"With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss," ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

A doctor has revealed six of the biggest mistakes people on weight loss drugs can make. Nobody's perfect, but when it comes ...

Treatment with the anti-obesity medications can reduce health risks for patients with heart failure by more than 40%. These ...